517 related articles for article (PubMed ID: 17335844)
1. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
Bertolotto A; Sala A; Caldano M; Capobianco M; Malucchi S; Marnetto F; Gilli F
J Immunol Methods; 2007 Apr; 321(1-2):19-31. PubMed ID: 17335844
[TBL] [Abstract][Full Text] [Related]
2. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort.
McKay F; Schibeci S; Heard R; Stewart G; Booth D
J Immunol Methods; 2006 Mar; 310(1-2):20-9. PubMed ID: 16448664
[TBL] [Abstract][Full Text] [Related]
3. Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay.
Massart C; Gibassier J; Oger J; Le Page E; Edan G
Clin Chim Acta; 2007 Feb; 377(1-2):185-91. PubMed ID: 17123498
[TBL] [Abstract][Full Text] [Related]
4. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis.
Deisenhammer F; Schellekens H; Bertolotto A
J Neurol; 2004 Jun; 251 Suppl 2():II31-9. PubMed ID: 15264110
[TBL] [Abstract][Full Text] [Related]
5. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients.
Lam R; Farrell R; Aziz T; Gibbs E; Giovannoni G; Grossberg S; Oger J
J Immunol Methods; 2008 Jul; 336(2):113-8. PubMed ID: 18511063
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.
Farrell RA; Espasandin M; Lakdawala N; Creeke PI; Worthington V; Giovannoni G
Mult Scler; 2011 Nov; 17(11):1333-40. PubMed ID: 21685230
[TBL] [Abstract][Full Text] [Related]
7. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
[TBL] [Abstract][Full Text] [Related]
8. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study.
Millonig A; Rudzki D; Hölzl M; Ehling R; Gneiss C; Künz B; Berger T; Reindl M; Deisenhammer F
Mult Scler; 2009 Aug; 15(8):977-83. PubMed ID: 19465447
[TBL] [Abstract][Full Text] [Related]
9. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
Hesse D; Sellebjerg F; Sorensen PS
Neurology; 2009 Aug; 73(5):372-7. PubMed ID: 19652141
[TBL] [Abstract][Full Text] [Related]
10. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity.
Sominanda A; Rot U; Suoniemi M; Deisenhammer F; Hillert J; Fogdell-Hahn A
Mult Scler; 2007 Mar; 13(2):208-14. PubMed ID: 17439886
[TBL] [Abstract][Full Text] [Related]
11. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
Pachner AR; Cadavid D; Wolansky L; Skurnick J
Neurology; 2009 Nov; 73(18):1485-92. PubMed ID: 19884576
[TBL] [Abstract][Full Text] [Related]
12. IFNbeta bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays.
Capra R; Sottini A; Cordioli C; Serana F; Chiarini M; Caimi L; Padovani A; Bergamaschi R; Imberti L
J Neuroimmunol; 2007 Sep; 189(1-2):102-10. PubMed ID: 17619058
[TBL] [Abstract][Full Text] [Related]
13. Predictive markers for response to interferon therapy in patients with multiple sclerosis.
Malucchi S; Gilli F; Caldano M; Marnetto F; Valentino P; Granieri L; Sala A; Capobianco M; Bertolotto A
Neurology; 2008 Mar; 70(13 Pt 2):1119-27. PubMed ID: 18272865
[TBL] [Abstract][Full Text] [Related]
14. Identification of interferon-beta antibodies in a reference laboratory setting: findings for 1144 consecutive sera.
Prince HE; Lapé-Nixon M; Audette C; Van Horn K
J Neuroimmunol; 2007 Oct; 190(1-2):165-9. PubMed ID: 17889376
[TBL] [Abstract][Full Text] [Related]
15. Antibodies against interferon-beta in multiple sclerosis.
Aarskog NK; Marøy T; Myhr KM; Vedeler CA
J Neuroimmunol; 2009 Jul; 212(1-2):148-50. PubMed ID: 19467718
[TBL] [Abstract][Full Text] [Related]
16. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.
Pachner AR; Dail D; Pak E; Narayan K
J Neuroimmunol; 2005 Sep; 166(1-2):180-8. PubMed ID: 16005084
[TBL] [Abstract][Full Text] [Related]
17. Development of a bioassay for quantification of neutralising antibodies against human interferon-beta in mouse sera.
Gilli F; van Beers M; Marnetto F; Jiskoot W; Bertolotto A; Schellekens H
J Immunol Methods; 2008 Jul; 336(2):119-26. PubMed ID: 18558408
[TBL] [Abstract][Full Text] [Related]
18. Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis.
Gilli F; Marnetto F; Caldano M; Sala A; Malucchi S; Di Sapio A; Capobianco M; Bertolotto A
J Neuroimmunol; 2005 Jan; 158(1-2):195-203. PubMed ID: 15589054
[TBL] [Abstract][Full Text] [Related]
19. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.
Gilli F; Valentino P; Caldano M; Granieri L; Capobianco M; Malucchi S; Sala A; Marnetto F; Bertolotto A
Neurology; 2008 Dec; 71(24):1940-7. PubMed ID: 18971450
[TBL] [Abstract][Full Text] [Related]
20. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
van der Voort LF; Kok A; Visser A; Oudejans CB; Caldano M; Gilli F; Bertolotto A; Polman CH; Killestein J
Mult Scler; 2009 Feb; 15(2):212-8. PubMed ID: 18805837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]